Shehryar R Sheikh1, Michael W Kattan1, Michael Steinmetz1, Mendel E Singer1, Belinda L Udeh1, Lara Jehi2. 1. From the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (S.R.S.); Department of Quantitative Health Sciences (M.W.K., B.L.U.), Department of Neurological Surgery (M.S.), and Epilepsy Center (L.J.), Cleveland Clinic; and Department of Population and Quantitative Health Sciences (M.E.S.), Case Western Reserve University, Cleveland, OH. 2. From the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (S.R.S.); Department of Quantitative Health Sciences (M.W.K., B.L.U.), Department of Neurological Surgery (M.S.), and Epilepsy Center (L.J.), Cleveland Clinic; and Department of Population and Quantitative Health Sciences (M.E.S.), Case Western Reserve University, Cleveland, OH. jehil@ccf.org.
Abstract
OBJECTIVE: Surgery is an effective but costly treatment for many patients with drug-resistant temporal lobe epilepsy (DR-TLE). We aim to evaluate whether, in the United States, surgery is cost-effective compared to medical management for patients deemed surgical candidates and whether surgical evaluation is cost-effective for patients with DR-TLE in general. METHODS: We use a semi-Markov model to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. We use second-order Monte Carlo simulations to conduct probabilistic sensitivity analyses to estimate variation in model output. We adopt both health care and societal perspectives, including direct health care costs (e.g., surgery, antiepileptic drugs) and indirect costs (e.g., lost earnings by patients and care providers.) We compare the incremental cost-effectiveness ratio to societal willingness to pay (∼$100,000 per quality-adjusted life-year [QALY]) to determine whether surgery is cost-effective. RESULTS: Epilepsy surgery is cost-effective compared to medical management in surgically eligible patients by virtue of being cost-saving ($328,000 vs $423,000) and more effective (16.6 vs 13.6 QALY) than medical management in the long run. Surgical evaluation is cost-effective in patients with DR-TLE even if the probability of being deemed a surgical candidate is only 5%. From a societal perspective, surgery becomes cost-effective within 3 years, and 89% of simulations favor surgery over the lifetime horizon. CONCLUSION: For surgically eligible patients with DR-TLE, surgery is cost-effective. For patients with DR-TLE in general, referral for surgical evaluation (and possible subsequent surgery) is cost-effective. Patients with DR-TLE should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.
OBJECTIVE: Surgery is an effective but costly treatment for many patients with drug-resistant temporal lobe epilepsy (DR-TLE). We aim to evaluate whether, in the United States, surgery is cost-effective compared to medical management for patients deemed surgical candidates and whether surgical evaluation is cost-effective for patients with DR-TLE in general. METHODS: We use a semi-Markov model to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. We use second-order Monte Carlo simulations to conduct probabilistic sensitivity analyses to estimate variation in model output. We adopt both health care and societal perspectives, including direct health care costs (e.g., surgery, antiepileptic drugs) and indirect costs (e.g., lost earnings by patients and care providers.) We compare the incremental cost-effectiveness ratio to societal willingness to pay (∼$100,000 per quality-adjusted life-year [QALY]) to determine whether surgery is cost-effective. RESULTS: Epilepsy surgery is cost-effective compared to medical management in surgically eligible patients by virtue of being cost-saving ($328,000 vs $423,000) and more effective (16.6 vs 13.6 QALY) than medical management in the long run. Surgical evaluation is cost-effective in patients with DR-TLE even if the probability of being deemed a surgical candidate is only 5%. From a societal perspective, surgery becomes cost-effective within 3 years, and 89% of simulations favor surgery over the lifetime horizon. CONCLUSION: For surgically eligible patients with DR-TLE, surgery is cost-effective. For patients with DR-TLE in general, referral for surgical evaluation (and possible subsequent surgery) is cost-effective. Patients with DR-TLE should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.
Authors: Nathalie Jette; Hude Quan; Jose F Tellez-Zenteno; Sophia Macrodimitris; Walter J Hader; Elisabeth M S Sherman; Lorie D Hamiwka; Elaine C Wirrell; Jorge G Burneo; Amy Metcalfe; Peter D Faris; Lizbeth Hernandez-Ronquillo; Churl-Su Kwon; Andrew Kirk; Samuel Wiebe Journal: Neurology Date: 2012-08-15 Impact factor: 9.910
Authors: J Engel; S Wiebe; J French; M Sperling; P Williamson; D Spencer; R Gumnit; C Zahn; E Westbrook; B Enos Journal: Neurology Date: 2003-02-25 Impact factor: 9.910
Authors: Jorge G Burneo; Vicente Villanueva; Robert C Knowlton; R Edward Faught; Ruben I Kuzniecky Journal: Seizure Date: 2007-11-19 Impact factor: 3.184
Authors: Lara Jehi; Nathalie Jette; Churl-Su Kwon; Colin B Josephson; Jorge G Burneo; Fernando Cendes; Michael R Sperling; Sallie Baxendale; Robyn M Busch; Chahnez Charfi Triki; J Helen Cross; Dana Ekstein; Dario J Englot; Guoming Luan; Andre Palmini; Loreto Rios; Xiongfei Wang; Karl Roessler; Bertil Rydenhag; Georgia Ramantani; Stephan Schuele; Jo M Wilmshurst; Sarah Wilson; Samuel Wiebe Journal: Epilepsia Date: 2022-07-17 Impact factor: 6.740
Authors: Wesley T Kerr; Xingruo Zhang; Chloe E Hill; Emily A Janio; Andrea M Chau; Chelsea T Braesch; Justine M Le; Jessica M Hori; Akash B Patel; Corinne H Allas; Amir H Karimi; Ishita Dubey; Siddhika S Sreenivasan; Norma L Gallardo; Janar Bauirjan; Eric S Hwang; Emily C Davis; Shannon R D'Ambrosio; Mona Al Banna; Andrew Y Cho; Sandra R Dewar; Jerome Engel; Jamie D Feusner; John M Stern Journal: Seizure Date: 2021-02-15 Impact factor: 3.184
Authors: Wesley T Kerr; Xingruo Zhang; Chloe E Hill; Emily A Janio; Andrea M Chau; Chelsea T Braesch; Justine M Le; Jessica M Hori; Akash B Patel; Corinne H Allas; Amir H Karimi; Ishita Dubey; Siddhika S Sreenivasan; Norma L Gallardo; Janar Bauirjan; Eric S Hwang; Emily C Davis; Shannon R D'Ambrosio; Mona Al Banna; Andrew Y Cho; Sandra R Dewar; Jerome Engel; Jamie D Feusner; John M Stern Journal: Seizure Date: 2021-02-09 Impact factor: 3.184
Authors: Steven Lenio; Wesley T Kerr; Meagan Watson; Sarah Baker; Chad Bush; Alex Rajic; Laura Strom Journal: Epilepsy Behav Date: 2021-02-02 Impact factor: 2.937
Authors: Erik Kaestner; Nigel P Pedersen; Ranling Hu; Armin Vosoughi; Abdulrahman Alwaki; Andres Rodriguez Ruiz; Ekaterina Staikova; Kelsey C Hewitt; Charles Epstein; Carrie R McDonald; Robert E Gross; Daniel L Drane Journal: Epileptic Disord Date: 2022-04-01 Impact factor: 2.333